Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03371979

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Sponsor: Aeglea Biotherapeutics

Conditions Small-cell Lung Cancer

Interventions Pegzilarginase Pembrolizumab

Updated 17 times since 2017 Last updated: Nov 3, 2021 Started: Dec 21, 2017 Primary completion: Jan 1, 2021 Completion: Jan 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Small-cell Lung Cancer and is currently completed. Aeglea Biotherapeutics leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2021 — Jun 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 12 earlier versions

Jun 2021 — Dec 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2021 — Jun 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jul 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2019 — Jul 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2019 — Jun 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Feb 2018 — May 2018 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aeglea Biotherapeutics
Merck Sharp & Dohme LLC

Data source: Aeglea Biotherapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Blacksburg, United States , Charleston, United States , Cincinnati, United States , Denver, United States , Detroit, United States , Germantown, United States , Houston, United States and 12 more locations